Back to Search Start Over

Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer

Authors :
Lambros Stamatakis
Jillian Egan
Chaoyi Zheng
Jonathan Hwang
Filipe L.F. Carvalho
Colleen Hamm Kelly
John H. Lynch
Ross Krasnow
Keith J. Kowalczyk
Alexander Zeymo
Source :
Investigative and Clinical Urology, Investigative and Clinical Urology, Vol 61, Iss 4, Pp 390-396 (2020)
Publication Year :
2020
Publisher :
The Korean Urological Association, 2020.

Abstract

Purpose: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is standard of care for muscle-invasive bladder cancer (MIBC). However, NAC is used in less than 20% of patients with MIBC. Our goal is to investigate factors that contribute to underutilization NAC to facilitate more routine incorporation into clinical practice. Materials and Methods: We identified 5,915 patients diagnosed with cT2-T3N0M0 MIBC who underwent RC between 2004 and 2014 from the National Cancer Database. Univariate and multivariable models were created to identify variables associated with NAC utilization. Results: Only 18.8% of patients received NAC during the study period. On univariate analyses, NAC utilization was more likely at academic hospitals, US South and Midwest (p

Details

Language :
English
ISSN :
2466054X and 24660493
Volume :
61
Issue :
4
Database :
OpenAIRE
Journal :
Investigative and Clinical Urology
Accession number :
edsair.doi.dedup.....e26ef344b7e32603a76955ca962c120f